Cell-in-a-Box® Insulin-Producing Cells
Type 1 & Insulin-dependent Type 2 Diabetes
PreclinicalOn Hold
Key Facts
Indication
Type 1 & Insulin-dependent Type 2 Diabetes
Phase
Preclinical
Status
On Hold
Company
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical-stage company developing localized cellular therapies for oncology and metabolic diseases via its Cell-in-a-Box® encapsulation technology, designed to protect implanted, engineered cells. Its most advanced program targeted locally advanced pancreatic cancer (LAPC) by activating chemotherapy at the tumor site. Since October 2022, the company has been in a strategic review, with all program spending curtailed, placing its future direction and pipeline advancement on hold pending the outcome of this evaluation.
View full company profile